Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials (US RLD: Vimpat). Lacosamide Injection is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures. It acts on the Central Nervous System (CNS) to reduce the number and severity of seizures. The drug will be manufactured at the group's injectables manufacturing facility at Jarod, India. Lacosamide Injection has a market size of USD 50 mn (as per IQVIA MAT May 22).
The group now has 316 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 356.75 as compared to the previous close of Rs. 356.05. The total number of shares traded during the day was 26277 in over 1183 trades.
The stock hit an intraday high of Rs. 359.05 and intraday low of 353.50. The net turnover during the day was Rs. 9353412.00.